Position in EBS
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$5,866
+$56 QoQ
Shares Held
700
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#154
of 193 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EBS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Triumph Capital Management holds $55,247 across 8 Drug Manufacturers - Specialty & Generic names. EBS ranks #4 (10.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
560 | $18,972 | |
| 2 | VTRS |
Viatris Inc
|
915 | $14,530 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
885 | $14,186 | |
| 4 | EBS |
Emergent BioSolutions Inc.
This page
|
700 | $5,866 | |
| 5 | ZTS |
Zoetis Inc.
|
21 | $1,509 | |
| 6 | HLN |
Haleon plc
|
18 | $167 | |
| 7 | CRON |
Cronos Group Inc.
|
6 | $16 | |
| 8 | BTAI |
BioXcel Therapeutics, Inc.
|
1 | $1 |
All Filings in EBS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,866 | 700 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $5,810 | 700 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $8,652 | 700 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||